Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review
The COVID‐19 pandemic has caused respiratory failure and associated mortality in numbers that have overwhelmed global health systems. Thrombotic coagulopathy is present in nearly three‐quarters of COVID‐19 patients admitted to the intensive care unit, and both the clinical picture and pathologic fin...
Main Authors: | Barrett, Christopher D., Moore, Hunter B., Moore, Ernest E., McIntyre, Robert C., Moore, Peter K, Burke, John, Hua, Fei, Apgar, Joshua, Talmor, Daniel S., Sauaia, Angela, Liptzin, Deborah R., Veress, Livia A., Yaffe, Michael B. |
---|---|
Other Authors: | Koch Institute for Integrative Cancer Research at MIT |
Format: | Article |
Published: |
Wiley
2020
|
Online Access: | https://hdl.handle.net/1721.1/125146 |
Similar Items
-
Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series
by: Wang, Janice, et al.
Published: (2020) -
Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis
by: Choudhury, Rashikh, et al.
Published: (2020) -
STudy of Alteplase for Respiratory failure in SARS‐Cov2/COVID‐19: Study Design of the Phase IIa STARS Trial
by: Moore, Hunter B., et al.
Published: (2020) -
Is there a role for tissue plasminogen activator (tPA) as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome (ARDS)?
by: Barrett, Christopher D., et al.
Published: (2020) -
Modern Management of Bleeding, Clotting, and Coagulopathy in Trauma Patients: What Is the Role of Viscoelastic Assays?
by: Dhara, Sanjeev, et al.
Published: (2021)